TGTX Tg Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TGTX

Price (delayed)

$15

Market cap

$2.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.46

Enterprise value

$2.17B

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
Tg Therapeutics's EPS has increased by 44% YoY and by 18% QoQ
The company's net income rose by 43% YoY and by 17% QoQ
The equity has dropped by 75% year-on-year and by 42% since the previous quarter
The revenue has shrunk by 58% YoY and by 45% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tgtherapeutics.com
Peers: INFI ALKS

Key stats

What are the main financial stats of TGTX
Market
Shares outstanding
146.36M
Market cap
$2.2B
Enterprise value
$2.17B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
37.21
Price to sales (P/S)
729.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
780.38
Earnings
Revenue
$2.79M
EBIT
-$188.14M
EBITDA
-$187.84M
Free cash flow
-$176.18M
Per share
EPS
-$1.46
Free cash flow per share
-$1.3
Book value per share
$0.4
Revenue per share
$0.02
TBVPS
$1.42
Balance sheet
Total assets
$193.57M
Total liabilities
$134.99M
Debt
$81.48M
Equity
$58.59M
Working capital
$115.07M
Liquidity
Debt to equity
1.39
Current ratio
3.16
Quick ratio
3.06
Net debt/EBITDA
0.12
Margins
EBITDA margin
-6,744.7%
Gross margin
90.5%
Net margin
-7,121.5%
Operating margin
-6,924.2%
Efficiency
Return on assets
-82.1%
Return on equity
-173%
Return on invested capital
-138.4%
Return on capital employed
-134%
Return on sales
-6,755.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
2.04%
1 week
2.74%
1 month
-5.84%
1 year
50.45%
YTD
26.8%
QTD
26.8%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$2.79M
Gross profit
$2.52M
Operating income
-$192.84M
Net income
-$198.34M
Gross margin
90.5%
Net margin
-7,121.5%
The revenue has shrunk by 58% YoY and by 45% QoQ
Tg Therapeutics's gross profit has shrunk by 57% YoY and by 45% QoQ
TGTX's net margin is down by 50% QoQ and by 37% YoY
Tg Therapeutics's operating margin has decreased by 49% QoQ and by 34% YoY

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
P/E
N/A
P/B
37.21
P/S
729.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
780.38
Tg Therapeutics's EPS has increased by 44% YoY and by 18% QoQ
The P/B is 193% above the last 4 quarters average of 12.7 and 110% above the 5-year quarterly average of 17.7
The equity has dropped by 75% year-on-year and by 42% since the previous quarter
The P/S is 198% above the last 4 quarters average of 244.6 but 89% below the 5-year quarterly average of 6505.2
The revenue has shrunk by 58% YoY and by 45% QoQ

Efficiency

How efficient is Tg Therapeutics business performance
TGTX's ROIC has soared by 84% YoY and by 22% QoQ
The company's return on equity has shrunk by 71% YoY and by 15% QoQ
Tg Therapeutics's return on sales has decreased by 47% QoQ and by 32% YoY
The ROA has contracted by 7% YoY

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 43% higher than the total liabilities
The total assets fell by 49% YoY and by 11% QoQ
TGTX's current ratio is down by 38% year-on-year and by 37% since the previous quarter
TGTX's debt is 39% higher than its equity
The equity has dropped by 75% year-on-year and by 42% since the previous quarter
The debt to equity has soared by 74% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.